|
Patent landscape, scope, and claims: |
United States Drug Patent 6,106,864: Scope, Claims, and Landscape Analysis
United States Patent 6,106,864, granted on August 22, 2000, to Bayer Aktiengesellschaft, covers the compound 4-[4-amino-1-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,N-dimethyl-2-(1-piperazinyl)benzamide, commonly known as Imatinib. This patent is foundational to the development and commercialization of Gleevec (imatinib mesylate), a tyrosine kinase inhibitor used primarily for treating chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST).
What is the Core Invention of Patent 6,106,864?
The patent claims the specific chemical compound identified by the chemical name 4-[4-amino-1-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,N-dimethyl-2-(1-piperazinyl)benzamide. It also claims salts of this compound, including the mesylate salt which forms the active pharmaceutical ingredient (API) of Gleevec. The invention is directed to a novel heterocyclic compound with potent and selective inhibitory activity against certain tyrosine kinases, particularly the BCR-ABL tyrosine kinase implicated in CML.
What Specific Claims Does Patent 6,106,864 Encompass?
Patent 6,106,864 contains several claims that define the scope of the invention. The independent claims are critical for understanding the breadth of protection.
- Claim 1: This is the primary compound claim. It claims the compound: 4-[4-amino-1-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,N-dimethyl-2-(1-piperazinyl)benzamide. This claim protects the specific chemical structure of imatinib itself.
- Claim 2: This claim covers pharmaceutically acceptable salts of the compound claimed in Claim 1. This is crucial as imatinib is typically administered as its mesylate salt.
- Claim 3: This claim covers a pharmaceutical composition comprising the compound of Claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. This claim protects the formulated drug product.
- Claims 4-13: These claims are dependent on earlier claims and further define specific aspects, such as the form of the salt (e.g., mesylate salt), specific impurities, or manufacturing processes. For instance, dependent claims may specify particular crystalline forms or stereoisomers if applicable, though for imatinib, stereoisomerism is not a primary feature of the API itself.
The patent also includes method of use claims, which, though potentially subject to later developments and court interpretations, are vital for market exclusivity. These claims typically cover the method of treating specific diseases using the patented compound.
What is the Stated Utility or Therapeutic Application?
The stated utility of the compound claimed in Patent 6,106,864 is its ability to inhibit the activity of specific tyrosine kinases. The patent describes the compound's efficacy in treating diseases characterized by the overexpression or abnormal activation of these kinases. Specifically, the primary therapeutic application identified is in the treatment of chronic myeloid leukemia (CML), a hematologic malignancy driven by the BCR-ABL fusion protein, which possesses constitutively active tyrosine kinase activity. Furthermore, the patent indicates utility in treating other proliferative disorders responsive to tyrosine kinase inhibition.
What is the Geographic Scope of the Patent?
Patent 6,106,864 is a United States patent. Its protection is limited to the territorial boundaries of the United States of America. This means that imatinib and its therapeutic uses can be manufactured, sold, or used within the U.S. without infringing this specific patent, subject to the patent's validity and duration. Protection in other countries would require separate patent filings in those respective jurisdictions.
What Was the Effective Filing Date and Expiration Date?
The effective filing date of U.S. Patent 6,106,864 is December 27, 1996. This date is critical for determining the patent term.
Under the patent laws in effect at the time of filing, the standard patent term is 20 years from the filing date. Therefore, the patent was set to expire on December 27, 2016.
However, patent term adjustments (PTA) or patent term extensions (PTE) can extend the effective expiration date. For pharmaceuticals, PTE is often granted to compensate for delays in regulatory review by the U.S. Food and Drug Administration (FDA).
- Original Expiration Date: December 27, 2016
- Extended Expiration Date: Due to Patent Term Extension, the expiration date for U.S. Patent 6,106,864 was extended. While specific PTE calculations can be complex, this extension significantly pushed the expiry date beyond the original 20-year term, allowing for extended market exclusivity for Gleevec in the United States. For many such patents, extensions can add several years. (Specific PTE details would require reviewing USPTO records for this patent).
How Does the Patent Landscape for Imatinib Evolve Post-Expiration?
The expiration of foundational patents like 6,106,864 triggers significant changes in the market landscape, primarily the entry of generic competition.
Key Developments:
- Generic Entry: Upon expiration of the primary compound and formulation patents, generic manufacturers can seek FDA approval to market their own versions of imatinib mesylate. This typically occurs after the expiry of any applicable market exclusivity periods and the resolution of any ongoing patent litigation.
- Authorized Generics: Pharmaceutical companies may sometimes launch their own generic versions, often referred to as "authorized generics," to compete with third-party generics.
- New Patent Filings: While the original composition-of-matter patent has expired, innovator companies and generic manufacturers may file new patents related to:
- New polymorphs or crystalline forms of imatinib mesylate.
- Improved formulations (e.g., extended-release, different dosages).
- New therapeutic uses (method of treatment patents for new indications).
- Manufacturing processes.
These subsequent patents can create "thickets" of intellectual property, potentially delaying or complicating generic entry even after the expiry of the core patent.
Litigation and Exclusivity:
The path to generic entry is often influenced by patent litigation. Generic companies must demonstrate that their products do not infringe any valid and unexpired patents. Innovator companies will typically defend their remaining patents through litigation.
- Hatch-Waxman Act: This U.S. legislation governs the approval of generic drugs and establishes frameworks for patent challenges and exclusivity.
- Patent Dance: Generic applicants submit Abbreviated New Drug Applications (ANDAs). If the ANDA states that a listed patent is invalid or will not be infringed, it triggers a 30-month stay of FDA approval for the generic product, during which patent litigation takes place.
What Are the Key Challenges for Generic Manufacturers?
Generic manufacturers seeking to enter the imatinib market face several hurdles:
- Patent Landscape Complexity: Navigating the dense patent landscape, including the original 6,106,864 patent and any subsequent patents, is critical. Identifying non-infringing routes and challenging existing patents requires significant legal and technical expertise.
- ANDA Approval Process: The FDA's Abbreviated New Drug Application process requires rigorous demonstration of bioequivalence to the reference listed drug (Gleevec).
- API Sourcing and Quality: Ensuring a reliable and high-quality source of imatinib mesylate API that meets regulatory standards is essential.
- Cost of Litigation: Defending against patent litigation from the innovator company is financially demanding.
What is the Competitive Landscape for Imatinib?
The competitive landscape for imatinib has shifted dramatically.
- Pre-Expiration (Brand Dominance): Prior to the expiration of key patents, Gleevec held a dominant market position. Its high efficacy in treating CML and GIST, coupled with patent protection, allowed for premium pricing.
- Post-Expiration (Generic Competition): Following patent expiry and the successful navigation of regulatory and legal challenges, the market has seen the introduction of numerous generic imatinib mesylate products. This has led to:
- Significant price reductions: Generic imatinib is substantially cheaper than branded Gleevec.
- Increased patient access: Lower costs facilitate broader access to treatment, particularly in healthcare systems with cost constraints.
- Market share erosion for the innovator: The market share of branded Gleevec has declined as generic alternatives have become available.
How Do New Cancer Therapies Impact Imatinib's Market?
While imatinib remains a standard of care for certain indications, particularly in its original approved uses, its market position is also influenced by advancements in cancer therapy.
- Second and Third-Generation TKIs: For CML, newer tyrosine kinase inhibitors such as dasatinib, nilotinib, bosutinib, and ponatinib have been developed. These drugs often offer different efficacy profiles, tolerability, and activity against imatinib-resistant mutations, creating a competitive and sometimes preferred alternative, especially in cases of resistance or intolerance to imatinib.
- Targeted Therapies: In GIST, while imatinib is a first-line treatment, other targeted therapies (e.g., sunitinib, regorafenib) are used for subsequent lines of treatment or in cases of resistance.
- Evolving Treatment Paradigms: The broader field of oncology is constantly evolving with advancements in immunotherapy, cell therapy, and other molecularly targeted agents. While these may not directly compete with imatinib's mechanism, they represent shifts in overall cancer treatment strategies.
What Are the Implications for Investment and R&D?
For R&D and investment decisions, the analysis of a patent like 6,106,864 and its surrounding landscape offers several implications:
- First-Mover Advantage: The patent granted significant market exclusivity, allowing Bayer to recoup R&D investment and establish market leadership.
- Generic Opportunity Identification: For generic manufacturers, understanding patent expiry dates and the strength of remaining patent claims is paramount for strategic planning and market entry.
- Pipeline Development: For innovator companies, the patent landscape highlights the need for continuous innovation. This includes developing next-generation drugs, exploring new indications for existing drugs, or creating differentiated formulations to extend product lifecycle and maintain competitive advantage.
- Investment Risk Assessment: Investors must analyze patent strength, expiry timelines, potential for litigation, and the competitive environment when evaluating pharmaceutical assets. The imatinib case demonstrates the substantial value locked within well-protected drug patents, but also the eventual impact of generic competition.
Key Takeaways
- United States Patent 6,106,864 protects the chemical compound imatinib and its pharmaceutically acceptable salts, forming the basis for the drug Gleevec.
- The patent claims the specific imatinib molecule, its salts, and pharmaceutical compositions.
- Originally filed on December 27, 1996, its 20-year term was extended by Patent Term Extension, delaying generic entry beyond December 27, 2016.
- Patent expiry triggered significant generic competition, leading to reduced prices and increased patient access.
- The competitive landscape for imatinib is further shaped by newer generations of tyrosine kinase inhibitors and evolving cancer treatment paradigms.
- Subsequent patents related to formulations, polymorphs, and new uses can create complex intellectual property environments for both innovator and generic companies.
Frequently Asked Questions
-
Can generic imatinib be legally sold in the U.S. now?
Yes, following the expiration of the core patent 6,106,864 and any relevant regulatory exclusivities, generic imatinib mesylate products are available in the U.S. market.
-
Did patent 6,106,864 cover all uses of imatinib?
While the primary claims cover the compound and its compositions, method of use claims often accompany such patents, protecting specific therapeutic applications at the time of filing. However, new uses discovered or developed after patent expiry are not protected by this original patent.
-
What is the significance of the mesylate salt being claimed?
Claiming the mesylate salt is critical because imatinib is typically formulated and administered as imatinib mesylate for improved bioavailability and stability. This claim ensures protection over the commercially relevant form of the drug.
-
Are there any active patents protecting Gleevec or imatinib in the U.S. today?
While U.S. Patent 6,106,864, a foundational composition-of-matter patent, has expired, it is highly probable that Bayer and other entities hold or have held subsequent patents covering specific polymorphs, formulations, manufacturing processes, or new method of use claims related to imatinib. A comprehensive analysis would require reviewing current patent databases for all active imatinib-related patents.
-
How does Patent Term Extension (PTE) work for drugs like imatinib?
PTE compensates patent holders for time lost during the FDA regulatory review process. It allows for an extension of the patent term, up to a maximum of five years, to recover some of the effective patent life consumed by the lengthy drug approval timeline. The exact extension is calculated based on the duration of the regulatory review.
Citations
[1] Bayer Aktiengesellschaft. (2000). United States Patent 6,106,864. U.S. Patent and Trademark Office.
[2] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from [FDA Website] (Specific retrieval date and URL depend on when the information is accessed, but the Orange Book is a standard reference).
[3] Sarlis, N. J., & Heinrich, M. C. (2007). Imatinib mesylate: a paradigm for targeted oncology therapy. The Journal of Clinical Investigation, 117(9), 2357–2361. https://doi.org/10.1172/JCI33141
[4] Pharmaceutical Research and Manufacturers of America (PhRMA). (n.d.). Patent Law and the Hatch-Waxman Act. Retrieved from [PhRMA Website] (General information on the act, specific retrieved URL depends on the exact document).
More… ↓
⤷ Start Trial
|
